Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06454409 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06454409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06454409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Suspended
Start date
May 21, 2025
Completion date
September 6, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome/acute myeloid leukemia, recurrent acute myeloid leukemia, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory myelodysplastic syndrome